The role of moxifloxacin in tuberculosis therapy

Download figure
Open in new tab
Download powerpoint
FIGURE 1
Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary tuberculosis: REMoxTB [9], RIFAQUIN [10] and OFLOTUB [11]. Note that moxifloxacin/rifapentine 900 mg was administered twice weekly and moxifloxacin/rifapentine 1200 mg was administered weekly. H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; M: moxifloxacin; Rp: rifapentine (with a subscript defining dose); G: gatifloxacin; ep, mp, rp and hp: placebos for ethambutol, moxifloxacin, rifampicin and isoniazid, respectively; LJ: Lowenstein–Jensen; MGIT: Mycobacteria Growth Indicator Tube.

TABLE 1

Summary of 4-month treatment trials in pulmonary tuberculosis, indicating their design, unfavourable rate and follow-up

Study [ref.]	Experimental regimen duration	Regimens	Patients on experimental arms n	Relapse or unfavourable rate %	Follow-up
Second French study [79]	18 weeks	2SHRZ/HRZ	180^#	3	24 months
*Mehrotra et al. [80]*	19 weeks	3SHRZ/RH		0	12 months
		3SHRZ/SHZ		0
		3SHRZEmide		5
East African/British Medical Research Council [81]	19 weeks	2SHRZ/2HRZ	104	16	24 months
		2SHRZ/2RH	104	11
		2SHRZ/2HZ	98	32
		2SHRZ/2H	105	30
		2HRZ/2H	100	40
Singapore/British Medical Research Council [82]	4 months	2SHRZ/HRZ	80	11	>24 months
Singapore/British Medical Research Council [82]		2SHRZ/HR	81	6
REMoxTB [9]	17 weeks	2MHRZ/2MHR	655	15	12 months
REMoxTB [9]		2EMRZ/2MR	636	20
RIFAQUIN [10]	4 months	2MHRZ/2MRp (twice weekly)	275	18.2	12–18 months
OFLOTUB [11]	4 months	2HRZG/2HR	694	21	24 months

S: streptomycin; H: isoniazid; R: rifampicin; Z: pyrazinamide; Emide: ethionamide; M: moxifloxacin; E: ethambutol; Rp: rifapentine; G: gatifloxacin ^#: 204 patients in the trial and data analysed from 180.